PrimeInvestor - Articles and Reports
Prime NCD review – Should you invest in Muthoot Fincorp NCD?
With yields for the Muthoot Fincorp NCD ranging from 9.26% to 9.75%, find out if you should go for it.
Prime Stock update โ A shift to Hold for this auto ancillary companyย
A sharp rally resulting in rich valuations have prompted us to move this auto ancillary stock to a ‘HOLD’.
Prime NCD review – Should you invest in Muthoot Finance NCD?
Muthoot Finance, a non-deposit taking NBFC, registered with RBI, has come up with a public offering of secured NCDs for an amount aggregating to Rs.100 crore. Find out if you should go for it.
Book review: Unlocking Nalanda Capitalโs best guarded investment formula
A review of Pulak Prasadโs book – What I learned about investing from Darwin.
Muthoot Microfin IPO: Should you invest?
Should you invest in the Rs. 960 crore Muthoot Microfin IPO? Find out in this detailed review.
Tata Technologies IPO: Should you invest?
The Tata Technologies IPO comes almost 2 decades after the earlier IPO from the Tata group. In this report, you will find out if you should invest in this IPO.
Small Finance Banks: What drives their strong performance ย
Small Finance Banks have been getting a lot of attention lately. Deep dive into how they have performed and understand what’s behind their success and more.
Prime Stocks update: Exit call on this EV playerย
With the evolution of the EV marketplace taking shape a little differently from when we gave a BUY call on this stock, we think it would now be best to EXIT this EV player.
Is the Buffett indicator (Market cap to GDP ratio) the right indicator for stock market valuation?ย
Theoretically, market cap follows GDP but this doesn’t work perfectly in real life. Understand the Buffett Indicator and how to interpret it in this article.
Prime Stock alert: Moving this auto play to a HOLD again
With the background of the recent rally, we are moving this auto play to a ‘HOLD’ so you don’t enter at high valuations.
Prime Stock alert: Moving this pharma stock to a HOLD
Recent announcements relating to ownership change in this pharma stock prompt us to move this stock from a ‘BUY’ to a ‘HOLD’.